Cuts, scrapes, blisters, burns, splinters, and punctures—there are a number of ways our skin can be broken.
Most treatments for skin wounds involve simply placing a barrier over it (usually an adhesive gauze bandage) to keep it moist, limit pain, and reduce exposure to infectious microbes, but do not actively assist in the healing process.
More sophisticated wound dressings that can monitor aspects of healing such as pH and temperature and deliver therapies to a wound site have been developed in recent years, but they are complex to manufacture, expensive, and difficult to customize, limiting their potential for widespread use.
Now, a new, scalable approach to speeding up wound healing has been developed based on heat-responsive hydrogels that are mechanically active, stretchy, tough, highly adhesive, and antimicrobial: active adhesive dressings (AADs).
Created by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Harvard’s John A. Paulson School for Engineering and Applied Sciences (SEAS), and McGill University, AADs can close wounds significantly faster than other methods and prevent bacterial growth without the need for any additional apparatus or stimuli.
The research is reported in Science Advances.
“This technology has the potential to be used not only for skin injuries, but also for chronic wounds like diabetic ulcers and pressure sores, for drug delivery, and as components of soft robotics-based therapies,” said corresponding author David Mooney, Ph.D.
AADs take their inspiration from developing embryos, whose skin is able to heal itself completely, without forming scar tissue.
To achieve this, the embryonic skin cells around a wound produce fibers made of the protein actin that contract to draw the wound edges together, like a drawstring bag being pulled closed.
Skin cells lose this ability once a fetus develops past a certain age, and any injuries that occur after that point cause inflammation and scarring during the healing process.
In order to mimic the contractile forces that pull embryonic skin wounds closed, the researchers extended the design of previously developed tough adhesive hydrogels by adding a thermoresponsive polymer known as PNIPAm, which both repels water and shrinks at around 90° F.
The resulting hybrid hydrogel begins to contract when exposed to body temperature, and transmits the force of the contracting PNIPAm component to the underlying tissue via strong bonds between the alginate hydrogel and the tissue.
In addition, silver nanoparticles are embedded in the AAD to provide antimicrobial protection.
“The AAD bonded to pig skin with over ten times the adhesive force of a Band-Aid? and prevented bacteria from growing, so this technology is already significantly better than most commonly used wound protection products, even before considering its wound-closing properties,” said Benjamin Freedman, Ph.D.
To test how well their AAD closed wounds, the researchers tested it on patches of mouse skin and found that it reduced the size of the wound area by about 45% compared to almost no change in area in the untreated samples, and closed wounds faster than other treatments including microgels, chitosan, gelatin, and other types of hydrogels.
The AAD also did not cause inflammation or immune responses, indicating that it is safe for use in and on living tissues.
Furthermore, the researchers were able to adjust the amount of wound closure performed by the AAD by adding various amounts of acrylamide monomers during the manufacturing process.
“This property could be useful when applying the adhesive to wounds on a joint like the elbow, which moves around a lot and would probably benefit from a looser bond, compared to a more static area of the body like the shin,” said co-first author Jianyu Li, Ph.D., a former Postdoctoral Fellow at the Wyss Institute who is now an Assistant Professor at McGill University.
The team also created a computer simulation of AAD-assisted wound closure, which predicted that AAD could cause human skin to contract at a rate comparable to that of mouse skin, indicating that it has a higher likelihood of displaying a clinical benefit in human patients.
“We are continuing this research with studies to learn more about how the mechanical cues exerted by AAD impact the biological process of wound healing, and how AAD performs across a range of different temperatures, as body temperature can vary at different locations,” said Benjamin Freedman, Ph.D., a Postdoctoral Fellow in the Mooney lab who is taking the lead on the project.
“We hope to pursue additional preclinical studies to demonstrate AAD’s potential as a medical product, and then work toward commercialization.”
“This is another wonderful example of a mechanotherapy in which new insights into the key role that physical forces play in biological control can be harnessed to develop a new and simpler therapeutic approach that may be even more effective than drugs or complex medical devices,” said Wyss Founding Director Donald Ingber, M.D.
Written by Lindsay Brownell.
